This guide provides actionable tips for medical device manufacturers on how to effectively respond to FDA cybersecurity deficiency letters and additional information requests, aiming for a cleared submission and market launch without delays.
Major deficiencies typically allow 180 days to respond. Miss it and the submission is withdrawn.
Recognize the 180-day FDA response window and the escalating costs of delays, including engineering hours, missed launches, and potential for additional deficiency rounds.
Address deficiencies quickly to avoid extended FDA holds, which can lead to significant revenue impact and investor scrutiny.
Dissect the FDA hold letter line by line to accurately identify specific reviewer requests and the exact evidence needed for a complete response.
When the FDA requests additional information, provide precise and complete answers that directly address every question without oversharing unnecessary details.
Rebuild or strengthen flagged threat models to meet FDA expectations, ensuring alignment with AAMI TIR57 and industry best practices.
Conduct or redo penetration testing to address any gaps identified by the FDA, providing clear and reviewer-grade evidence of vulnerability management.
Identify and address missing documentation, such as incomplete SBOMs, SPDFs, or weak risk assessments, and build out the necessary artifacts.
Compile and format the entire deficiency response package, ensuring it is ready for eSTAR upload and easy consumption by the FDA reviewer.
Update risk assessments with clear traceability to ISO 14971 and ensure all cybersecurity documentation, including threat models, are connected to patient harm.
Authoritative guidance and standards underpinning this topic. Always confirm the latest revision with the publisher.
Quick answers to the questions teams most often ask about this topic.
A cybersecurity deficiency letter is FDA feedback (typically part of an Additional Information request during 510(k)/De Novo/PMA review) identifying gaps in your cybersecurity submission. It stops the review clock until you provide an adequate response.
Address every question point-by-point with concrete evidence, not restated claims. Attach updated threat models, SBOM/VEX, test reports, or labeling as appropriate. When you disagree with a finding, provide a rationale grounded in your risk management file rather than pushing back stylistically.
Typically 180 days for 510(k)/De Novo, though the specific letter will state the deadline. Extensions are possible but require justification and may signal to reviewers that the underlying issue is unresolved.
Threat models missing STRIDE coverage per interface, no SBOM or non-machine-readable SBOM, missing VEX, penetration test scope that omits an interface, no coordinated vulnerability disclosure policy, and labeling that omits cybersecurity information required under the 2026 guidance.
Yes. A brief pre-response teleconference through your Regulatory Project Manager (RPM) is often the fastest way to resolve ambiguity, especially on threat-modeling scope or SBOM depth. It costs nothing and typically shortens the overall cycle.